A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Launched by BOEHRINGER INGELHEIM · Oct 16, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for adults in Asia who have advanced solid tumors, such as gastrointestinal, lung, pancreatic, colorectal, head and neck, or liver cancer. The study is looking at how well a medication called BI 765049 works alone and when combined with another medication, ezabenlimab. The goal is to find the highest safe dose of these medications and see if they can help shrink tumors in patients whose previous treatments haven’t worked or where no other treatment options are available. To join the study, participants must have a specific marker called B7-H6 present in their tumors.

Eligible participants are adults aged 18 and older who have been diagnosed with advanced cancer that cannot be surgically removed. They will receive treatment every three weeks for up to three years, going to a study site for infusions of the medications. During their time in the trial, doctors will closely monitor their health, check for any side effects, and measure how well the treatment is working by looking at the size of the tumors. This study aims to learn more about these medications and how they can help improve cancer treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed and dated, written inform consent form (ICF) (ICF1 for B7-H6 testing for all patients except those with colorectal cancer (CRC); ICF2 for all patients) describing the study in accordance with International Council on Harmonisation Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
• • ≥18 years of age at the time of signature on the ICFs (ICF1 and ICF2).
• • Histologically or cytologically confirmed diagnosis of an advanced, unresectable, and/or metastatic gastrointestinal cancer, colorectal cancer, pancreatic cancer, liver cancer, head and neck cancer, or lung cancer.
• • Disease progression despite conventional treatment, intolerant to or not a candidate for conventional treatment, or with a tumour for which no conventional treatment exists.
• • Agree to the collection of tumour samples (as slides from archival diagnostic samples or fresh tumour biopsies) for confirmation of B7-H6 expression at Screening Visit 02 for colorectal cancer (CRC) patients or at Screening Visit 01 for all other patients.
• • Confirmed B7-H6 expression on tumour tissue sample (archived or fresh tumour biopsy) based on central pathology review except for patients diagnosed with advanced or metastatic colorectal cancer (CRC).
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• • At least one evaluable target lesion as defined per response evaluation criteria in solid tumors (RECIST v1.1), outside of the central nervous system (CNS), separate from any lesion(s) identified for tumour biopsy. Tumour lesions that have been irradiated ≥28 days before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions only in the absence of measurable lesions that have not been irradiated.
• • Further inclusion criteria apply
• Exclusion Criteria:
• • History of a major surgery within 28 days prior to first dose of BI 765049 (major according to the Investigator's assessment).
• * Previous or concomitant malignancies other than the one treated in this trial within the last 3 years except:
• • Effectively treated non-melanoma skin cancers
• • Effectively treated carcinoma in situ of the cervix
• • Effectively treated ductal carcinoma in situ
• • Other effectively treated malignancy that is considered cured by local treatment
• • Known leptomeningeal disease or spinal cord compression due to disease.
• • Require anticoagulant treatment which cannot be safely interrupted, if medically needed for a study procedure (e.g., biopsy) based on the opinion of the Investigator.
• * Hepatitis C virus (HCV) infection, defined as:
• • Currently receiving curative antiviral treatment for HCV infection, and/or
• • HCV viral load is above the limit of quantification (HCV Ribonucleic acid (RNA) positive)
• • Hepatitis B virus (HBV) infection with the following laboratory evidence: positive results of hepatitis B surface (HBs) antigen and presence of Hepatitis B core (HBc) antibody together with HBV-deoxyribonucleic acid (DNA).
• • Presence of any infection requiring systemic antimicrobial treatment within 7 days prior to first dose of trial medication. Patients who have any clinical signs of infection (e.g. fever or leukocytosis) within 48 hours prior to first dose of trial medication are not eligible.
• * Patients with known history of human immunodeficiency virus (HIV) infection who meet one or more of the following criteria:
• • Cluster of differentiation 4 (CD4+) count \<350 cells/μL (local lab assessment)
• • Viral load \>400 copies/mL (local lab assessment)
• • Not receiving antiretroviral therapy
• • Receiving established antiretroviral therapy for less than four weeks prior to the start of study treatment
• • History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months prior to start of study treatment Patients with a history of HIV who do not meet any of the criteria above are eligible to participate, but the patient must be under the care of a HIV/Infectious Diseases specialist, or a HIV/Infectious Diseases specialist must be consulted prior to inclusion.
• • Further exclusion criteria apply